SenzaGen
SenzaGen is a Swedish biotech providing animal-free, genomics-based immunotoxicological testing of chemical compounds. Founded in 2010 in Lund, it serves cosmetics, pharmaceutical, and chemical manufacturers seeking in vitro alternatives to in vivo safety testing.
- Company typePrivate
- Founded2010
- HeadquartersLund, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingServices
What SenzaGen does
SenzaGen is a Swedish biotechnology company founded in 2010 and headquartered in Lund, Sweden, that provides animal-free testing of chemical compounds using a genomics-based methodology for immunotoxicological assays. The company replaces traditional in vivo animal testing with in vitro genomic profiling designed to assess whether chemical substances can trigger allergic or immunotoxic responses. Its primary customer base is implied to be cosmetics, pharmaceutical, and chemical product manufacturers and formulators that must demonstrate product safety and regulatory compliance, particularly in jurisdictions restricting or banning animal testing.
The company operates with a small team of 11-50 employees and has secured public grant funding, including approximately $2.55 million from the European Innovation Council and SMEs Executive Agency (EISMEA) in March 2017. SenzaGen reported a Q4 EBIT loss of SEK 4.0 million, indicating that the company has not yet reached breakeven and is likely in an early commercialization phase. No pricing model, go-to-motion, or specific product catalog details are disclosed in the available source data. A large block of reported financial figures in the source feed (revenues stated in trillions of USD with corresponding losses in hundreds of billions) is implausible for a sub-50-employee private Swedish biotech and is treated as a data quality artifact rather than verified company financials.
Governance is led by Peter Nählstedt as President and CEO, with Anki Malmborg also listed as CEO (a co-leadership or succession arrangement) and Malin Lindstedt identified as founder. The company's underlying technology combines genomics profiling with immunotoxicological assay design, positioning it within the broader alternative-testing services market that benefits from regulatory tailwinds against animal testing.
SenzaGen firmographics
Firmographics- Name
- SenzaGen
- Website
- https://senzagen.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SenzaGen is a Swedish biotech providing animal-free, genomics-based immunotoxicological testing of chemical compounds. Founded in 2010 in Lund, it serves cosmetics, pharmaceutical, and chemical manufacturers seeking in vitro alternatives to in vivo safety testing.
- Ownership category
- akta.pro rank
SenzaGen industry classification
Industry- Product category
- In Vitro Toxicology Testing Services
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- Services-Testing Laboratories (8734)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
- akta.pro secondary industries
- Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF), Residue & Contaminant Testing (Pesticides, Vet Drugs, Mycotoxins, Heavy Metals) (AFALAAAF)
Keywords
Where SenzaGen is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Markets served
SenzaGen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
SenzaGen product offering
Product offeringCore offering
SenzaGen provides animal-free in vitro testing of chemical compounds using a genomics-based methodology for immunotoxicological assays. The offering enables industrial customers to assess the sensitizing potential of chemical substances without using animal models. The company is positioned as an alternative to traditional animal-based toxicology testing.
Differentiator
Problem solved
Functional benefit
Products and services
- Animal-free immunotoxicology testing services
Companies that use SenzaGen
Customer profileIdeal customer profiles1 record
SenzaGen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
SenzaGen partnerships and signals
Strategic signalScale indicators1 record
Recent moves2 records
Expansion highlights2 records
SenzaGen competitors and assessment
Company assessmentEmerging players
- Gentronix: Specialist in vitro genotoxicity and toxicology services company with a portfolio of non-animal assays (e.g., GreenScreen HC, GADD45a). Comparable to SenzaGen as a small specialist CRO selling mechanism-based in vitro toxicology assays to regulated chemical and pharma customers.
- Cellular Dynamics International (Fujifilm): Provider of human iPSC-derived cell models and toxicology services used as in vitro alternatives for drug and chemical safety testing. Comparable because its cell-based assays overlap with the non-animal testing workflow that SenzaGen's genomic immunotoxicology platform addresses.
Broad incumbents
- Eurofins Scientific: Global testing services giant with extensive in vitro toxicology, REACH, and chemical safety testing capabilities. Comparable because it serves the same regulated chemical/cosmetics customers seeking non-animal toxicology data and dwarfs SenzaGen in scale and menu breadth.
- Charles River Laboratories: Major CRO offering both in vivo and in vitro safety assessment, including immunotoxicology and specialty toxicology panels. Comparable because it competes for the same regulated safety-testing budgets and has been actively expanding non-animal alternatives.
- Bio-Rad Laboratories: Life-science tools and diagnostics company with broad genomics, cell biology, and quality-control reagent offerings used in toxicology labs. Comparable because its genomic and proteomic reagent platforms underpin the same kind of in vitro toxicology workflows SenzaGen runs.
Others
- Promega Corporation: Provider of genomic, cell-based, and toxicity-testing reagents and kits to academic and industrial labs. Comparable because its reagents (e.g., for cytotoxicity, genotoxicity, and biomarker assays) are often used in the same non-animal toxicology workflows as SenzaGen's services.
- BioIVT: Supplier of human and animal biological specimens, including samples used in immunology and toxicology research. Comparable as an enabling supplier to the in vitro immunotoxicology testing ecosystem in which SenzaGen operates.
- Genedata: Provider of bioinformatics software used to analyze omics data (genomics, proteomics, screening) in drug discovery and toxicology workflows. Comparable as a technology enabler for the genomic data analysis pipeline that underpins SenzaGen's assay platform.
Direct peers
- Cyprotex (Evotec): Specialist in vitro ADME and toxicology CRO with a strong focus on non-animal assays for chemicals and pharmaceuticals. Closely comparable to SenzaGen as both sell in vitro toxicology testing services to regulated industries using mechanistic/omics-based methods.
- MatTek Life Sciences: Developer and provider of in vitro human tissue models (e.g., EpiDerm for skin irritation, ocular models) used as non-animal alternatives in regulatory toxicology testing. Comparable because it sells directly into the same animal-free safety testing market that SenzaGen targets with its immunotoxicology assays.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
SenzaGen social profiles
Digital presenceSenzaGen financial estimates
Financial estimateRevenue estimate
Valuation estimate
SenzaGen leadership team
Management profileNumber of profiles
Profiles3 records
SenzaGen funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SenzaGen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SenzaGen
What does SenzaGen do?
SenzaGen provides animal-free in vitro testing of chemical compounds using a genomics-based methodology for immunotoxicological assays. The offering enables industrial customers to assess the sensitizing potential of chemical substances without using animal models. The company is positioned as an alternative to traditional animal-based toxicology testing.
Is SenzaGen a public or private company?
SenzaGen is a private company. It is classified as venture growth investor backed and is currently operating.
When was SenzaGen founded?
SenzaGen was founded in 2010. It employs 11 to 50 people.
Where is SenzaGen based?
SenzaGen is headquartered in Lund, Sweden, in the Europe region.
Who are SenzaGen's main competitors?
Emerging players on record are Gentronix and Cellular Dynamics International (Fujifilm). Broad incumbents are Eurofins Scientific, Charles River Laboratories and Bio-Rad Laboratories. Others are Promega Corporation, BioIVT and Genedata. Direct peers are Cyprotex (Evotec) and MatTek Life Sciences.
Does SenzaGen have an API?
No public API is recorded for SenzaGen.
What industry is SenzaGen in?
SenzaGen's product category is In Vitro Toxicology Testing Services. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAFAMAF, Toxicology & Therapeutic Drug Monitoring Laboratories. Its NAICS code is 325413 and its SIC code is 8734.